Ilya Pharma will present Poster with AMR data for ILP100 at US military medical partnering conference MHSRS August 26-29 August, Kissimmee, FL

Ilya Pharma will present new data in antimicrobial resistance (AMR) and the bacterial killing activity of ILP100 on multi-drug-resitant (MDR) pathogenic bacteria isolated from War victims in Ukraine.

Ilya Pharma presents clinical update at 9th Microbiome Movement Drug Development Summit, Boston 10-12 July

New publication in American Journal of Physiology Gastrointestinal and Liver on the MOA and PoC for ILP100-Oral in multiple models of colitis

The work is funded by Ilya Pharma AB, Bio-X grant from STUNS in Uppsala and the Knut and Alice Wallenberg Foundation.

Open position part-time accounting assistant

The company is insourcing business administration.

Presentation of new data of antimicrobial effects on multi-drug resistant bacterial infections from Ukraine war victims

CXCL12-expressing Limosilactobacillus reuteri has clinically relevant antimicrobial effects of multidrug-resistant bacteria isolated from wounds of war victims in Ukraine Presented by Dr Andreas Fasth Poster ID 939

One PhD Position in chemokine immunobiology - HORIZON-MSCA-2022-DN Doctoral Network “B-ACTIVE”

Ilya Pharma gives an update at Pharmabiotics in Lille, France March 13-15

Ilya Pharma presents at Biologics World Nordic in Copenhagen March 6-7

Ilya Pharma presents at Uppsala University Pharmaceutical Science Day 1st February in Uppsala

Ilya Pharma receives funding by HORIZON Marie Sklodowska-Curie Doctoral Network B-ACTIVE